Two humanized DLL4 antibodies—enoticumab (REGN421) and demcizumab (OMP-21M18)—have shown preliminary anti-tumor activity in ovarian cancer and other solid tumors in phase I studies143,144. Here, DLL4 is linked to ovarian cancer.